SCHEMBL4432735

SCHEMBL4432735

Nc1nc(-c2ccc(/C=C/C(=O)NO)cc2)cs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 3/20 0.54
PARP1 P09874 1/20 0.53
HDAC2 Q92769 7/20 0.53
HDAC4 P56524 4/20 0.53
HDAC1 Q13547 4/20 0.53
HDAC6 Q9UBN7 4/20 0.53
HDAC8 Q9BY41 3/20 0.53
HDAC3 O15379 2/20 0.53
HDAC7 Q8WUI4 2/20 0.53
HDAC10 Q969S8 2/20 0.53
HDAC11 Q96DB2 2/20 0.53
HDAC9 Q9UKV0 2/20 0.53
HDAC5 Q9UQL6 2/20 0.53
LTA4H P09960 1/20 0.51
MKNK1 Q9BUB5 1/20 0.51
MKNK2 Q9HBH9 1/20 0.51
MAPT P10636 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
RAB9A P51151 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4432736 1.00 KDM4E (0.54) KDM4EALDH1A1PARP1HDAC2HDAC4
Hydrochloric Acid SCHEMBL5453430 0.99 KDM4E (0.52) KDM4EALDH1A1PARP1HDAC2HDAC4
Hydrochloric Acid SCHEMBL5453426 0.99 KDM4E (0.52) KDM4EALDH1A1PARP1HDAC2HDAC4
SCHEMBL4420218 0.80 PARP1 (0.64) KDM4EALDH1A1PARP1HDAC4MAPT
SCHEMBL4420213 0.80 PARP1 (0.64) KDM4EALDH1A1PARP1HDAC4MAPT
SCHEMBL4423752 0.78 CA12 (0.55) KDM4EALDH1A1LTA4HMKNK1MKNK2
SCHEMBL4423750 0.78 CA12 (0.55) KDM4EALDH1A1LTA4HMKNK1MKNK2
SCHEMBL14449008 0.75 HDAC1 (0.70) KDM4EPARP1HDAC2HDAC4HDAC1
SCHEMBL1771825 0.74 ALDH1A1 (0.79) KDM4EALDH1A1LTA4HMKNK1MKNK2
SCHEMBL12425705 0.72 HDAC2 (0.64) HDAC2HDAC4HDAC1HDAC6HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1682538-A4 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S BIO PTE LTD (SG) 2009-05-27 EP claimed
EP-1682538-A1 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*Bio Pte Ltd (SG) 2006-07-26 EP claimed
WO-2005040161-A1 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*BIO PTE LTD (SG) 2005-05-06 WO claimed
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 US disclosed
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 US disclosed
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 US disclosed
WO-2005040161-A1 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*BIO PTE LTD (SG) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications HDAC1, HDAC11, HDAC2 KDM4E 454/4885ALDH1A1 447/4885PARP1 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.